Digital Quantification of Intratumoral CD8+ T-Cells Predicts Relapse and Unfavorable Outcome in Uveal Melanoma.
immunohistochemistry
prognosis
tumor microenvironment
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Dec 2022
02 Dec 2022
Historique:
received:
08
09
2022
revised:
20
09
2022
accepted:
26
09
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
Although it is a disease that occurs mainly in the Caucasian population, uveal melanoma (UM) is the most common primary intraocular tumor in adults. Here, we used digital pathology and image analysis for the diagnosis of UM and the prediction of the prognosis. Our retrospective study included a total of 404 histopathological slides from 101 patients. A digital image acquisition and quantitative analysis of tissue immune biomarkers (CD4, CD8, CD68, CD163) were performed. A negative impact of the intratumoral CD8 positive cell density higher than 13.3 cells/mm
Identifiants
pubmed: 36497441
pii: cancers14235959
doi: 10.3390/cancers14235959
pmc: PMC9740732
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ocul Oncol Pathol. 2022 Feb;8(1):35-41
pubmed: 35356606
Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1414-21
pubmed: 11381040
Ocul Oncol Pathol. 2018 Apr;4(3):145-151
pubmed: 29765944
Semin Diagn Pathol. 2016 May;33(3):141-7
pubmed: 26972224
Indian J Ophthalmol. 2015 Feb;63(2):93-102
pubmed: 25827538
Oncotarget. 2015 Nov 10;6(35):37824-35
pubmed: 26462151
Br J Ophthalmol. 2013 Feb;97(2):159-63
pubmed: 23159448
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
Anticancer Res. 2017 Dec;37(12):6541-6549
pubmed: 29187428
Melanoma Res. 2019 Jun;29(3):248-253
pubmed: 30480620
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Mol Cancer Res. 2018 Dec;16(12):1902-1911
pubmed: 30093564
Ophthalmology. 2007 Dec;114(12):2309-15
pubmed: 17498805
Int J Cancer. 2019 Nov 15;145(10):2611-2618
pubmed: 30989643
Arch Ophthalmol. 1977 Jan;95(1):63-9
pubmed: 836204
Cancer Immunol Immunother. 2017 Jul;66(7):903-912
pubmed: 28391358
J Immunol. 2017 Oct 1;199(7):2191-2193
pubmed: 28923980
Pathology. 2013 Jan;45(1):18-27
pubmed: 23222249
Cancer Med. 2019 Jun;8(6):3036-3046
pubmed: 31025552
Cancer Immunol Res. 2016 Mar;4(3):194-203
pubmed: 26787823
Oncologist. 2016 Jul;21(7):848-54
pubmed: 27286787
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Nat Commun. 2020 Jan 24;11(1):496
pubmed: 31980621
Nat Commun. 2017 Jul 24;8:16041
pubmed: 28737175
Invest Ophthalmol Vis Sci. 2011 Feb 03;52(2):643-50
pubmed: 20811059
Cancer Immunol Immunother. 2007 Nov;56(11):1687-700
pubmed: 17571260
J Immunol Res. 2021 Jun 11;2021:9920234
pubmed: 34195299
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):505-10
pubmed: 18234992
Cancer. 2016 Aug 1;122(15):2299-312
pubmed: 26991400
Front Cell Dev Biol. 2021 May 28;9:673838
pubmed: 34124058
Cancers (Basel). 2019 Jul 26;11(8):
pubmed: 31357439
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3282-7
pubmed: 12882771
Front Immunol. 2012 Jun 13;3:148
pubmed: 22707951
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Oncoimmunology. 2014 Oct 31;8(10):e947169
pubmed: 31646061
J Innate Immun. 2012;4(5-6):454-62
pubmed: 22302072
Hum Pathol. 2017 Aug;66:159-166
pubmed: 28655639
Eur J Ophthalmol. 2013 Mar-Apr;23(2):208-16
pubmed: 23065853
Cancer. 1990 Jan 1;65(1):112-5
pubmed: 2293857
Jpn J Ophthalmol. 2019 Mar;63(2):197-209
pubmed: 30796549
Eye (Lond). 2009 Oct;23(10):1885-9
pubmed: 19136922
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907